BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Harvard Business School
Deloitte
Farmers Insurance
Johnson and Johnson
Covington
Fuji
Federal Trade Commission
UBS
US Army

Generated: January 18, 2018

DrugPatentWatch Database Preview

Valeant Company Profile

« Back to Dashboard

Summary for Valeant
International Patents:802
US Patents:47
Tradenames:102
Ingredients:80
NDAs:125

Drugs and US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl LIBRITABS chlordiazepoxide TABLET;ORAL 085481-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharm Intl ELDECORT hydrocortisone CREAM;TOPICAL 084055-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms North NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 075269-002 Dec 4, 2000 AB1 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-003 Sep 8, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-003 Dec 24, 1985 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharm Intl LEVO-DROMORAN levorphanol tartrate INJECTABLE;INJECTION 008719-001 Dec 19, 1991 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Intl HYTONE hydrocortisone CREAM;TOPICAL 080472-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms North MINITRAN nitroglycerin FILM, EXTENDED RELEASE;TRANSDERMAL 089772-001 Aug 30, 1996 AB1 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 ➤ Subscribe ➤ Subscribe
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 ➤ Subscribe ➤ Subscribe
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM diltiazem hydrochloride TABLET;ORAL 018602-002 Nov 5, 1982 ➤ Subscribe ➤ Subscribe
Valeant Pharms North VASOTEC enalapril maleate TABLET;ORAL 018998-003 Dec 24, 1985 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 ➤ Subscribe ➤ Subscribe
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 ➤ Subscribe ➤ Subscribe
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-002 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 5/22/2014
➤ Subscribe Tablets 1.1 g ➤ Subscribe 11/5/2013
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 3/11/2013
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 4/3/2012
➤ Subscribe Cream 0.5% ➤ Subscribe 7/29/2011
➤ Subscribe Capsules 75 mg ➤ Subscribe 6/6/2011
➤ Subscribe Gel 0.04% ➤ Subscribe 12/20/2010
➤ Subscribe Gel 0.1% ➤ Subscribe 7/8/2010
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 12/24/2009
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 9/28/2009
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 9/24/2009
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 12/23/2008
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 12/8/2008
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 9/25/2007
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 3/28/2007
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 1/8/2007
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 8/30/2005
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 4/25/2005
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 9/21/2004
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 3/23/2004
Premature patent expirations for VALEANT

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Valeant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,504,640 Modified release formulations of a bupropion salt ➤ Subscribe
6,699,843 Method for treatment of tumors using nucleic acid ligands to PDGF ➤ Subscribe
6,682,886 Bivalent binding molecules of 7 transmembrane G protein-coupled receptors ➤ Subscribe
5,795,721 High affinity nucleic acid ligands of ICP4 ➤ Subscribe
5,874,218 Method for detecting a target compound in a substance using a nucleic acid ligand ➤ Subscribe
7,964,572 High affinity nucleic acid ligands of complement system proteins ➤ Subscribe
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Subscribe
5,843,653 Method for detecting a target molecule in a sample using a nucleic acid ligand ➤ Subscribe
6,184,364 High affinity nucleic acid ligands containing modified nucleotides ➤ Subscribe
7,939,654 Platelet derived growth factor (PDGF) nucleic acid ligand complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Drugs

Country Document Number Estimated Expiration
Greece 3025594 ➤ Subscribe
Hungary 0202221 ➤ Subscribe
Australia 1623299 ➤ Subscribe
Spain 2139063 ➤ Subscribe
Japan 4335975 ➤ Subscribe
Austria 274520 ➤ Subscribe
Canada 2360748 ➤ Subscribe
Australia 4018400 ➤ Subscribe
China 1589908 ➤ Subscribe
Norway 994431 ➤ Subscribe
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Valeant Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00053 Denmark ➤ Subscribe PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
C/GB10/012 United Kingdom ➤ Subscribe PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
00037 Netherlands ➤ Subscribe PRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
01C/010 Belgium ➤ Subscribe PRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215
90041 Netherlands ➤ Subscribe PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
C0042 Belgium ➤ Subscribe PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
C0062 France ➤ Subscribe PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
20/2006 Austria ➤ Subscribe PRODUCT NAME: PEGAPTANIB UND SALZE DAVON
00043 Netherlands ➤ Subscribe PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
2010 00009 Denmark ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Covington
Medtronic
Boehringer Ingelheim
Dow
Deloitte
Chinese Patent Office
Mallinckrodt
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot